Linezolid treatment of vancomycin-resistant Enterococcus faecium ventriculitis

Pediatr Infect Dis J. 2002 Aug;21(8):798-800. doi: 10.1097/00006454-200208000-00025.

Abstract

The successful treatment of a 7-month-old infant with shunt-associated ventriculitis caused by vancomycin-resistant Enterococcus faecium is presented. Linezolid was administered intravenously every 8 h; children have a greater volume of distribution and total body clearance than adults and therefore require more frequent dosing. The patient tolerated the therapy without adverse effects.

Publication types

  • Case Reports

MeSH terms

  • Acetamides / therapeutic use*
  • Anti-Bacterial Agents / therapeutic use
  • Encephalitis / drug therapy*
  • Encephalitis / microbiology*
  • Enterococcus faecium / isolation & purification*
  • Gram-Positive Bacterial Infections / drug therapy*
  • Gram-Positive Bacterial Infections / microbiology*
  • Humans
  • Hydrocephalus / drug therapy
  • Hydrocephalus / microbiology
  • Infant
  • Linezolid
  • Male
  • Oxazolidinones / therapeutic use*
  • Vancomycin Resistance*
  • Ventriculoperitoneal Shunt / adverse effects

Substances

  • Acetamides
  • Anti-Bacterial Agents
  • Oxazolidinones
  • Linezolid